Compositions and methods for treating or ameliorating mycobacterial infections

a technology for bacterial infections and compositions, applied in the direction of antibacterial agents, peptide/protein ingredients, endopeptidase, etc., can solve the problems of insufficient treatment to prevent the spread of the disease, the patient's behavior is often difficult to monitor, and the severity of complications and death is typically high, so as to achieve high activity and be recognized as useful

Inactive Publication Date: 2010-06-03
SHAPIRO LELAND
View PDF43 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0041]Also contemplated within the scope of the present invention is a method of preventing a deficiency of functional endogenous α1-antitrypsin levels in a patient susceptible to a mycobacterial infection of macrophages that is mediated by endogenous host serine protease or serine protease-like activity, by treating with a pharmaceutical composition in a pharmaceutically acceptable carrier comprising effective amounts of a substance exhibiting mammalian α1-antitrypsin or inhibitor of serine protease activity. The pharmaceutical composition can be a peptide or a small molecule, which exhibits α1-antitrypsin or inhibitor of serine protease activity.
[0043]In another aspect, the present invention provides a method for preventing a symptom of anthrax in a subject suspected of having been exposured to Bacillus anthracis comprising administering to the subject a pharmaceutically effective amount of a substance exhibiting mammalian α1-antitrypsin or inhibitor of serine protease activity, wherein said mammalian α1-antitrypsin or inhibitor of serine protease activity substance inhibits the endogenous host protease cell-surface processing of inactive large PA into the active smaller PA molecule, and wherein if the subject is exposed to Bacillus anthracis, a symptom of said exposure is prevented.
[0050]One aspect of the present invention is to provide clinically acceptable serine protease inhibitors with recognized utility and exhibiting relatively high activity at relatively low concentrations.

Problems solved by technology

If left untreated, serious complications and death typically result.
Although it is known that tuberculosis can generally be controlled using extended antibiotic therapy, such treatment is not sufficient to prevent the spread of the disease.
Infected individuals may be asymptomatic, but contagious, for some time.
In addition, although compliance with the specific treatment regimen is critical, patient behavior is often difficult to monitor.
As a result, some patients do not complete the course of treatment, thus leading to ineffective treatment and development of antibiotic resistance.
Some countries, such as the United States, however, do not vaccinate the general public because of concerns regarding the safety and efficacy of BCG.
However, this does not lead to complete eradication of the bacilli.
In contrast, B lymphocytes do not appear to be involved, and passive transfer of anti-mycobacterial antibodies does not provide any protective immunity.
The identity of the protease has been the focus of scant research effort, and it is poorly characterized.
LF is a metalloprotease that can kill macrophages or, at lower concentrations, induce macrophages to overproduce cytokines, possibly resulting in death of the host.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treating or ameliorating mycobacterial infections
  • Compositions and methods for treating or ameliorating mycobacterial infections
  • Compositions and methods for treating or ameliorating mycobacterial infections

Examples

Experimental program
Comparison scheme
Effect test

examples

[0198]The following specific examples are provided to better assist the reader in the various aspects of practicing the present invention. As these specific examples are merely illustrative, nothing in the following descriptions should be construed as limiting the invention in any way. Such limitations are, or course, defined solely by the accompanying claims.

example one

Effect of α1-Antitrypsin on Mycobacterium avium Complex (Mac) Infection of Human Monocyte-Derived Macrophages

[0199]1. TB or MAC organisms were suspended at a concentration of one Mcfarland standard. One McFarland is defined as a degree of turbidity of organisms suspended in liquid that matches that of a standard aliquot. A sample turbidity that is equivalent to that of the one McFarland standard represents about 10.sup.7 bacilli / ml. The optimal duration of a test culture is approximately 10-12 days of bacilli grown in Middlebrook 7H9 broth (=mycobacterium medium).

[0200]2. Infecting the cells. The cells infected were human monocyte-derived macrophages (MDM). MDM were isolated from human peripheral blood mononuclear cells (PBMC) that were obtained from heparinized blood from healthy volunteers by centrifuging the heparinized blood over a ficol-hypaque cushion. The isolated PBMC were aliquoted into polystyrene tissue culture plates and the monocytes are allowed to adhere .times.2 hrs (...

example two

Clinical Study in MAC Infection

[0217]The data described above in vitro using MAC have been supplemented with a clinical study. In this clinical investigation, AAT phenotypes (alternative forms of the AAT protein) were assessed in patients with documented lung infection with MAC and who had lung disease. These patients were compared to a control group consisting of patients with the lung disease bronchiectasis (in order to show that the presence of lung disease alone did not account for the presence of MAC infection).

BronchiectasisN = 134 subjectsMAC Infection (lungs)(lung disease)P-valueSex-Male8.97%23.21%Female91.3%76.79%Age (mean)64.5 yrs64.0 yrsATT phenotype (%0.006abnormal)-YES27.7% 5.3%NO72.3% 94.7%

[0218]Note in this table that that for the control (bronchiectasis) group, the proportion of patients with abnormal AAT molecules is 5.3%. This is in marked contrast to the case in the MAC.quadrature.infected group, where the proportion is 27.7%, a 5.2 fold increase. The MAC.quadratu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
molar concentrationsaaaaaaaaaa
molar concentrationsaaaaaaaaaa
Login to view more

Abstract

A novel method of treating and preventing bacterial diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of Gram negative, Gram poitive and acid fast bacilli in general and tuberculosis (TB), mycobacterium avium complex (MAC), and anthrax in particular. Thus, the invention relates to modulation of cellular activities, including macrophage activity, and the like. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a divisional of, and claims priority to, application Ser. No. 10 / 926,051 filed Aug. 26, 2004, which claims priority to provisional application Ser. No. 60 / 497,703 filed Aug. 26, 2003. Both applications are incorporated herein by reference in their entirety.FIELD OF THE INVENTION[0002]The present invention relates to compositions and methods for inhibition of bacterial infections comprising Gram negative, Gram positive, and acid fast bacilli in general and mycobacterium tuberculosis (TB), mycobacterium avium complex (MAC), and anthrax in particular, as well as to therapeutic treatment of diseases or disorders that involve infection of macrophages. Thus, the invention relates to modulation of cellular activities, including macrophage activity, inhibition of toxin, and the like. More particularly, the present invention also relates to inhibitory compounds comprising naturally occurring and man-made serine protease inhibit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/16A61K38/08A61P31/04A61K31/519A61K38/48A61K39/395C12NC12N9/64
CPCA61K31/519C07K2319/30C07K14/811C07K14/8125C07K2319/00C07K2319/21C07K2319/23C07K2319/43C07K2319/50A61K45/06C07K16/00C07K14/473A61K38/57A61K2300/00A61P31/04A61P31/06A61P31/08A61P43/00
Inventor SHAPIRO, LELAND
Owner SHAPIRO LELAND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap